In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are approved for clinical practice to reduce the risk of FN and its complications. Here, CSF3 is linked to cervical squamous intraepithelial neoplasia.